Mylab Discovery Solutions

Built India's first COVID-19 RT-PCR kit from scratch in six weeks at the start of the pandemic.

Positions itself around simplifying disease detection and lowering the cost of advanced diagnostics for the Indian market.

Brand promise centers on dependable test results across its instrument and kit portfolio.

Over 120 diagnostic products spanning molecular, POC, oncology, prenatal and applied-market testing, with a large real-world testing base.

Small to mid-cap laboratories that partner with Mylab to add molecular/in-vitro diagnostics capability, e.g. Dr. Rawal's Diagnostic & Research Lab in Virar, Mumbai, which built out its testing offering as a Mylab HealthTech Partner.

Businesses needing GMO detection, meat-species authentication and food-pathogen testing (AgroDex, VetScreen, PathoDetect product lines).

Other diagnostics companies that license or co-develop assays/instruments with Mylab under its OEM program, including a 2021 tie-up with US-based Hemex Health on point-of-care platforms.

National regulators/health system during COVID-19 — Mylab's RT-PCR, antigen and self-test kits were commercially approved by CDSCO, DCGI and ICMR for use in India's pandemic testing response.

Direct B2B channel that equips partner labs with kits, instruments, software, training and marketing/legal support to add Mylab diagnostics.

Co-development and technology-licensing channel with other diagnostics companies and device makers.

New products such as the PathoCatch COVID-19 antigen kit were made available for direct order immediately on approval.

Following its 2021 majority-stake acquisition of Sanskritech, Mylab distributes POC testing through doctor offices, nursing homes, community health centers and airports via lab partners.

Kit-manufacturing plant near Pune, the site backed by a Technology Development Board grant for COVID test-kit manufacturing.

R&D makes up the largest single share of Mylab's roughly 100-person team, per a 2020-era company profile.

Facilities hold ISO 9001 and ISO 13485 certification, supporting export and regulatory credibility.

Magnetic Bead Technology used for nucleic-acid extraction and multiplexing across its molecular product line.

Poonawalla partnered with and invested in Mylab in April 2020 to help scale COVID-19 test-kit production capacity.

Co-investor alongside Poonawalla in the April 2020 scale-up partnership; joined Mylab's board.

Gujarat-based diagnostics reagent maker that co-developed Mylab's PathoCatch COVID-19 antigen rapid test.

August 2021 technology partnership to co-develop point-of-care diagnostic platforms for COVID-19 and other diseases, targeting US, European and Asian markets.

Acquired a 6.5% equity stake in June 2023 through subsidiary Zydus Animal Health and Investments to participate in the diagnostics/point-of-care testing space.

Entered a grant agreement providing Rs 4 crore assistance against a Rs 13.6 crore project for manufacturing COVID testing kits at Mylab's Lonavala facility.

Core product line — PathoDetect, OncoScreen, NatSpert, DiscoverSeries, AgroDex kits and reagents sold to labs and partners.

Hardware revenue from automated systems such as Compact DX, MyBox, MyBeam and Compact XL.

COVID-19 RT-PCR, antigen and self-test kit sales drove revenue from operations up over 100x to Rs 825.42 crore in FY21 versus Rs 8.2 crore in FY20.

Fee-based OEM program offering consulting, manufacturing, design and regulatory support to other companies.